Stock 688319 CHENGDU OLYMVAX BIOPHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Chengdu Olymvax Biopharmaceuticals Inc.

Equities

688319

CNE1000051H8

End-of-day quote Shanghai S.E.
Other stock markets
 18:00:00 2024-06-20 EDT 		5-day change 1st Jan Change
10.25 CNY +4.81% Intraday chart for Chengdu Olymvax Biopharmaceuticals Inc. +2.50% -35.13%
05-16 Olymvax Biopharma's Flu Vaccine Gets China Nod for Clinical Trials MT
04-25 Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Olymvax Biopharma's Flu Vaccine Gets China Nod for Clinical Trials
MT
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Olymvax Biopharmaceuticals Withdraws Application for Combined Influenza Vaccine
MT
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Chinese healthcare stocks hit by stepped up anti-graft crackdown
RE
Olymvax Biopharma Gets Nod to Amend Packaging of Adsorbed Tetanus Vaccine
MT
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
Chengdu Olymvax Biopharmaceuticals Inc. has completed an IPO in the amount of CNY 400.4 million.
CI
Chengdu Olymvax Biopharmaceuticals Inc. has filed an IPO.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 688319 Stock
  4. News Chengdu Olymvax Biopharmaceuticals Inc.
  5. Highlights